Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roivant Sciences Ltd. - Common Shares (NQ:ROIV)

36.30 +0.25 (+0.69%)
Delayed Quote Updated: 3:31 PM EDT, Oct 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Roivant Sciences Ltd. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Roivant Sciences’ Brepocitinib Delivers Positive Phase III Uveitis Results ↗
Roivant Sciences (NASDAQ:ROIV) reported positive Phase III results from its CLARITY-1 and CLARITY-2 studies evaluating brepocitinib, which the company referred to as Brepo, in noninfectious uveitis... 
Via MarketBeat
Topics Government
News headline image
Roivant Sciences Targets LISRAYA Launch, Key Pipeline Readouts in Next 12 Months ↗
Roivant Sciences (NASDAQ:ROIV) CEO Matthew Gline outlined the company’s priorities for the next 12 months, including the launch of LISRAYA, upcoming clinical data for brepocitinib and Immunovant’s... 
Via MarketBeat
Topics Government
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
News headline image
Roivant Sciences Wins FDA Approval for LISRAYA in Dermatomyositis, Launches Immediately ↗
Roivant Sciences (NASDAQ:ROIV) said the U.S. Food and Drug Administration has approved LISRAYA, its once-daily oral therapy for adults with dermatomyositis, and that the drug has already entered... 
Via MarketBeat
Topics Government
ROIVANT SCIENCES LTD (NASDAQ:ROIV) Flashes Strong Breakout Setup with Near-Perfect Technical and Setup Quality Ratings ↗
Via Chartmill
Why Did Roivant Sciences Stock Gain 9% Pre-Market Today? ↗
Via Stocktwits
News headline image
Roivant Sciences Q1 Earnings Call Highlights ↗
Roivant Sciences (NASDAQ:ROIV) said it expects a busy second half of 2026, with a potential launch of brepocitinib in dermatomyositis, several clinical readouts and additional regulatory discussions... 
Via MarketBeat
Topics Earnings Government
News headline image
Could Roivant Sciences Be a Multibagger Stock Over the Next 5 Years? ↗
Wall Street expects sales to soar as several commercial launches approach. 
Via The Motley Fool
News headline image
Roivant (ROIV) Q4 2025 Earnings Transcript ↗
Roivant (ROIV) Q4 2025 Earnings Transcript 
Via The Motley Fool
News headline image
Roivant Sciences Q4 Earnings Call Highlights ↗
Roivant Sciences (NASDAQ:ROIV) executives used the company’s fourth-quarter earnings call to highlight new open-label data for IMVT-1402 in difficult-to-treat rheumatoid arthritis, upcoming pulmonary... 
Via MarketBeat
Topics Earnings Government
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
News headline image
Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval ↗
This biotech develops therapies for neurodegenerative diseases, advancing a broad pipeline through strategic pharmaceutical partnerships. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy? ↗
Beam Therapeutics develops precision genetic medicines using base editing technology to target serious inherited diseases. 
Via The Motley Fool
News headline image
Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy? ↗
Crinetics Pharmaceuticals develops oral therapies for rare endocrine diseases. 
Via The Motley Fool
Topics ETFs Regulatory Compliance
News headline image
Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares ↗
This biotech firm develops immunotherapies for cancer and autoimmune diseases, with several candidates advancing through clinical trials. 
Via The Motley Fool
News headline image
Roivant and Immunovant Solidify Market Leadership as Brepocitinib and FcRn Programs Hit Critical Clinical Milestones
The biotechnology sector witnessed a seismic shift this week as Roivant Sciences (Nasdaq: ROIV) and its subsidiary Immunovant (Nasdaq: IMVT) reported a series of clinical and regulatory updates that... 
Via MarketMinute
Topics Intellectual Property
News headline image
A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you? ↗
This clinical-stage biotech develops antibody therapies targeting autoimmune diseases, with a lead candidate in Phase II trials. 
Via The Motley Fool
News headline image
Moderna Settles High-Stakes LNP Patent War with $2.25 Billion Agreement
In a landmark resolution that removes a multi-year shadow over the messenger RNA (mRNA) industry, Moderna, Inc. (NASDAQ:MRNA) has reached a comprehensive $2.25 billion global settlement with Genevant... 
Via MarketMinute
Topics Intellectual Property Lawsuit
News headline image
BlackBarn Capital Builds Warby Parker Stake as the Direct-to-Consumer Eyewear Leader Expands Nationwide ↗
BlackBarn Capital has raised its investment in Warby Parker, a direct-to-consumer eyewear brand recognized for its affordable frames and expanding network of stores. As Warby Parker opens more... 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Moderna-Arbutus-Genevant Patent Settlement: Wall Street Says Not Best-Case Scenario But Removes Overhang For MRNA Stock ↗
The news is likely to come as a relief to many investors, Citi told investors in a research note. 
Via Stocktwits
Topics Intellectual Property
News headline image
MRNA Shares Rally After Hours On Inking Settlement Deal Over Vaccine Patent Row ↗
The settlement resolves all enforcement actions involving Moderna’s use of Genevant’s and Arbutus’ LNP delivery technology in its COVID-19 vaccines. 
Via Stocktwits
Topics Intellectual Property
News headline image
Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position ↗
Celcuity develops targeted cancer therapies and diagnostic platforms, with a focus on advancing precision medicine in oncology. 
Via The Motley Fool
News headline image
Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction ↗
Apogee Therapeutics develops biologic therapies targeting dermatology and respiratory conditions, with lead candidates in clinical trials. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Dolby Stock Down 18%, Yet This $8 Million Bet Signals Turnaround Potential ↗
This audio and imaging technology provider licenses Dolby Atmos and Vision to global entertainment and device markets. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
TTMI Stock Soars 250% in One Year, and One Fund Is Betting $7 Million on More Growth ↗
TTM Technologies supplies advanced printed circuit boards and RF components for high-reliability applications across diverse industries. 
Via The Motley Fool
Topics Artificial Intelligence Supply Chain
News headline image
Healthcare REIT Posts 16.4% NOI Growth as Shares Soar 93%: Why This Fund's New Stake Stands Out ↗
American Healthcare REIT manages a diverse portfolio of healthcare properties across the U.S. and U.K., serving institutional tenants. 
Via The Motley Fool
Topics Regulatory Compliance
The market is filled with gapping stocks in Friday's session. ↗
Via Chartmill
News headline image
Roivant Sciences (ROIV): Anatomy of a 15% Surge and the Future of the ‘Vant’ Model
As of February 6, 2026, Roivant Sciences (Nasdaq: ROIV) has firmly established itself as the preeminent "capital allocator" of the biotechnology sector. The company made headlines today with a... 
Via Finterra
Topics ETFs Economy Initial Public Offering
Get insights into the top gainers and losers of Friday's pre-market session. ↗
Via Chartmill
News headline image
The Great Rotation: Russell 2000’s Historic 15-Day Streak Marks a Seismic Shift in Market Leadership
In a move that has rewritten the record books of Wall Street, the small-cap-heavy Russell 2000 index recently concluded a historic 15-session winning streak of daily outperformance against the S&P 500.... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.